Sekar Kathiresan - 07 Jul 2022 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Executive Officer, Director
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Sekar Kathiresan
Issuer symbol
VERV
Transactions as of
07 Jul 2022
Net transactions value
$0
Form type
4
Filing time
15 Jul 2022, 17:00:27 UTC
Previous filing
22 Mar 2022
Next filing
21 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERV Common Stock Gift $0 -160,000 -33% $0.000000 317,839 07 Jul 2022 Direct F1, F2
transaction VERV Common Stock Gift $0 +160,000 +198% $0.000000 240,997 07 Jul 2022 Kathiresan Family 2021 Irrevocable Trust F1
holding VERV Common Stock 80,997 07 Jul 2022 Sekar Kathiresan 2021 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Gift $0 -140,000 -32% $0.000000 291,988 12 Jul 2022 Common Stock 140,000 $8.24 Direct F3, F4
transaction VERV Stock Option (right to buy) Gift $0 -160,000 -26% $0.000000 445,308 12 Jul 2022 Common Stock 160,000 $2.87 Direct F5, F6
transaction VERV Stock Option (right to buy) Gift $0 +140,000 $0.000000 140,000 12 Jul 2022 Common Stock 140,000 $8.24 Sekar Kathiresan 2022 Annuity Trust F3, F7
transaction VERV Stock Option (right to buy) Gift $0 +160,000 +114% $0.000000 300,000 12 Jul 2022 Common Stock 160,000 $2.87 Sekar Kathiresan 2022 Annuity Trust F5, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 7, 2022, the reporting person transferred 160,000 shares of Verve Therapeutics, Inc. (the "Company") common stock to a family trust. Members of the reporting person's immediate family are the beneficiaries of the trust.
F2 Includes 314 shares of the Company's common stock acquired under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan.
F3 On July 12, 2022, the reporting person transferred an employee stock option to purchase 140,000 shares of common stock of the Company to a grantor retained annuity trust of which the reporting person is trustee. The reporting person and members of his immediate family are the sole beneficiaries of the trust.
F4 The remaining shares underlying this option, which was granted on February 12, 2021, vest in equal monthly installments until February 1, 2025.
F5 On July 12, 2022, the reporting person transferred an employee stock option to purchase 160,000 shares of common stock of the Company to a grantor retained annuity trust of which the reporting person is trustee. The reporting person and members of his immediate family are the sole beneficiaries of the trust.
F6 The remaining shares underlying this option, which was granted on September 16, 2020, vest in equal monthly installments until September 16, 2024.
F7 The shares underlying the option being transferred were fully vested as of the date of transfer.